Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Terns Pharmaceuticals, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 44
- +7 vs. Q4 2021
- Shares held
- 16.8M
- +333.1K (+2.0%) vs. Q4 2021
- Total value
- $50.0M
- −$66.7M (−57.1%) vs. Q4 2021
- New holders
- 9
- 10 more added
- Sold out
- 2
- 14 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TERN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $75.4K |
| Q1 2026 | 317 | $6.56B |
| Q4 2025 | 248 | $4.95B |
| Q3 2025 | 141 | $665.7M |
| Q2 2025 | 130 | $310.0M |
| Q1 2025 | 138 | $229.4M |
| Q4 2024 | 157 | $477.2M |
| Q3 2024 | 156 | $663.1M |
| Q2 2024 | 126 | $446.7M |
| Q1 2024 | 112 | $414.8M |
| Q4 2023 | 103 | $412.7M |
| Q3 2023 | 93 | $310.4M |
| Q2 2023 | 103 | $505.0M |
| Q1 2023 | 79 | $630.2M |
| Q4 2022 | 65 | $506.2M |
| Q3 2022 | 45 | $178.1M |
| Q2 2022 | 42 | $36.5M |
| Q1 2022 | 44 | $50.0M |
| Q4 2021 | 37 | $116.7M |
| Q3 2021 | 34 | $174.3M |
| Q2 2021 | 36 | $203.8M |
| Q1 2021 | 42 | $393.7M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Terns Pharmaceuticals, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Hong Kong Ltd | 71 | $0 | 0.00% | +71 | New |
| Wells Fargo & Company | 613 | $2.00K | 0.00% | −4,866−88.8% | Reduced |
| Ameritas Investment Partners, Inc. | 708 | $2.00K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 1,067 | $3.00K | 0.00% | −3,219−75.1% | Reduced |
| Royal Bank of Canada | 843 | $3.00K | 0.00% | −2,231−72.6% | Reduced |
| Legal & General Group Plc | 1,454 | $4.00K | 0.00% | +175+13.7% | Added |
| Cubist Systematic Strategies, LLC | 1,200 | $4.00K | 0.00% | +1,200 | New |
| Amalgamated Bank | 2,079 | $6.00K | 0.00% | +2,079 | New |
| Amalgamated Financial Corp. | 2,079 | $6.00K | 0.00% | +2,079 | New |
| Tower Research Capital LLC (TRC) | 3,556 | $11.0K | 0.00% | +2,013+130.5% | Added |
| California State Teachers Retirement System | 5,987 | $18.0K | 0.00% | −2,173−26.6% | Reduced |
| New York State Common Retirement Fund | 5,918 | $18.0K | 0.00% | 00.0% | Unchanged |
| American International Group, Inc. | 6,811 | $20.0K | 0.00% | −478−6.6% | Reduced |
| Bank of America Corp | 7,224 | $21.0K | 0.00% | −1,361−15.9% | Reduced |
| Deutsche Bank AG | 8,033 | $24.0K | 0.00% | −878−9.9% | Reduced |
| Morgan Stanley | 8,491 | $25.0K | 0.00% | −80,965−90.5% | Reduced |
| JPMorgan Chase & Co | 9,367 | $28.0K | 0.00% | +1,923+25.8% | Added |
| Nuveen Asset Management, LLC | 14,237 | $43.0K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 15,352 | $46.0K | 0.00% | +15,352 | New |
| Goldman Sachs Group Inc | 16,427 | $49.0K | 0.00% | +1,219+8.0% | Added |
| Parametric Portfolio Associates LLC | 20,784 | $62.0K | 0.00% | +8,467+68.7% | Added |
| Marquette Asset Management, LLC | 21,802 | $65.0K | 0.02% | +5,183+31.2% | Added |
| Charles Schwab Investment Management Inc | 28,746 | $86.0K | 0.00% | 00.0% | Unchanged |
| Driehaus Capital Management LLC | 35,100 | $104.0K | 0.00% | +35,100 | New |
| Bank of New York Mellon Corp | 38,059 | $112.0K | 0.00% | +2,359+6.6% | Added |
| Bridgeway Capital Management, LLC | 62,700 | $186.0K | 0.00% | −32,800−34.3% | Reduced |
| Renaissance Technologies LLC | 67,800 | $201.0K | 0.00% | +67,800 | New |
| Cowen and Company, LLC | 85,000 | $252.0K | 0.03% | 00.0% | Unchanged |
| Caas Capital Management LP | 85,851 | $255.0K | 0.04% | 00.0% | Unchanged |
| Millennium Management LLC | 88,510 | $263.0K | 0.00% | +35,229+66.1% | Added |
| Northern Trust Corp | 104,822 | $311.0K | 0.00% | −7,214−6.4% | Reduced |
| Point72 Asset Management, L.P. | 122,573 | $364.0K | 0.00% | +122,573 | New |
| State Street Corp | 163,237 | $485.0K | 0.00% | +1,218+0.8% | Added |
| Geode Capital Management, LLC | 179,311 | $532.0K | 0.00% | −1,624−0.9% | Reduced |
| Samsara BioCapital, LLC | 289,068 | $859.0K | 0.22% | 00.0% | Unchanged |
| Vanguard Group Inc | 433,019 | $1.29M | 0.00% | −125,308−22.4% | Reduced |
| Decheng Capital Management III (Cayman), LLC | 714,285 | $2.12M | 0.65% | +714,285 | New |
| BlackRock Inc. | 736,941 | $2.19M | 0.00% | −8,594−1.2% | Reduced |
| Antara Capital LP | 1,074,834 | $3.19M | 0.25% | +125,000+13.2% | Added |
| Suvretta Capital Management, LLC | 1,238,800 | $3.68M | 0.11% | 00.0% | Unchanged |
| FMR LLC | 2,321,458 | $6.89M | 0.00% | −479,527−17.1% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 2,345,959 | $6.97M | 0.16% | 00.0% | Unchanged |
| Vivo Capital, LLC | 2,675,133 | $7.95M | 0.55% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 3,791,204 | $11.3M | 0.18% | 00.0% | Unchanged |
| Jacobs Levy Equity Management, Inc | 0 | $0 | 0.00% | −55,222−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,775−100.0% | Sold out |